Drug-drug interaction between antiacid and antiplatelet agents has not been fully elucidated. Vonoprazan, a new potassium competitive acid blocker, has been available in Japan. CYP2C19 and CYP3A4 are involved in the metabolism of clopidogrel, prasugrel, esomeprazole, and vonoprazan. Using a P2Y12 assay, we compared the effects of vonoprazan and esomeprazole on the antiplatelet functions of clopidogrel or prasugrel in 31 healthy Japanese volunteers (14 CYP2C19 homo-extensive (homo-EMs), nine hetero-extensive (hetero-EMs), and eight poor metabolizers (PMs)). Vonoprazan decreased the median inhibition of platelet aggregation (IPA) values of clopidogrel and prasugrel more potently than esomeprazole (P < 0.001 for clopidogrel and P 5 0.011 for prasugrel). The same tendencies were observed when stratified by CYP2C19 genotype groups (P 5 0.004 in homo-EMs, 0.033 in hetero-EMs, and 0.043 in PMs). Vonoprazan attenuated the antiplatelet function of clopidogrel more potently than esomeprazole. Esomeprazole did not affect that of prasugrel irrespective of CYP2C19 genotype.
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Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC? þ Clopidogrel is a first-line antiplatelet therapy for coronary heart disease. However, it is associated with gastrointestinal bleeding. To prevent gastrointestinal bleeding, proton pump inhibitors (PPIs) are recommended to be concomitantly used. Because of the drug-drug interaction between PPIs and clopidogrel, the selection of an appropriate gastric acid inhibitor for patients receiving clopidogrel remains an important clinical problem. The new acid inhibitor, vonoprazan, which is categorized to the potassium competitive acid blocker, is now available in Japan. The acid inhibitory effect of vonoprazan is superior to some PPIs such as esomeprazole and rabeprazole. Long-term use of vonoprazan is permitted for the prevention of recurrence of peptic ulcer in patients taking antiplatelet agents. However, the drug-drug interaction related to vonoprazan has not been fully elucidated.
WHAT QUESTION DID THIS STUDY ADDRESS?
þ This study mainly aimed to identify whether the new acid inhibitor, vonoprazan, attenuated antiplatelet function of clopidogrel or prasugrel by a crossover study using P2Y12 assay. If vonoprazan attenuated the antiplatelet function of clopidogrel and prasugrel, we would like to know the level of inhibition in reference to esomeprazole. Then we compared the drug-drug interaction potency of vonoprazan and esomeprazole on thienopyridines. WHAT DOES THIS STUDY ADD TO OUR KNOWLEDGE? þ We identified that vonoprazan attenuated the antiplatelet function of clopidogrel more potently than esomeprazole in the P2Y12 assay. Our results suggest that vonoprazan acts as an inhibitor not only for CYP3A4 but also CYP2C19. HOW THIS MIGHT CHANGE CLINICAL PHARMA-COLOGY OR TRANSLATIONAL SCIENCE? þ Vonoprazan should be recognized as not only the inhibitor of CYP3A4 but also the inhibitor of CYP2C19. Our study findings enhanced the understanding of the metabolic mechanisms of vonoprazan that influence antiplatelet response to clopidogrel and prasugrel treatment. These results suggest that the concomitant use of vonoprazan is not a better alternative PPI such as esomeprazole (S-isomer of omeprazole) in patients treated with clopidogrel.
Antiplatelet therapy is widely performed on patients with coronary heart disease, stroke, and peripheral artery disease. After implantation of bare metal or drug-eluting stents in the coronary artery, patients are generally prescribed dual antiplatelet therapy (DAPT) with aspirin and clopidogrel. 1 Gastrointestinal hemorrhage is a common serious complication of long-term antiplatelet therapy. 2 To prevent such bleeding events, a proton pump inhibitor (PPI) is often coadministered. 3 In 2008, the American College of Cardiology Foundation (ACCF), American College of Gastroenterology (ACG), and American Heart Association (AHA) recommended that patients with "a risk of peptic ulcer and/or two or more antiplatelet agents" should be prescribed a PPI. 4 However, drug-drug interactions between clopidogrel and PPIs have raised concern.
Thienopyridines are a class of drugs that inhibit adenosine diphosphate (ADP) P2Y12 platelet receptors. Clopidogrel, a second-generation thienopyridine agent, is a prodrug-it is only active after being metabolized. In the liver, clopidogrel is predominantly metabolized to its active form by CYP2C19 and CYP3A4 (Supplemental Figure S1 ), 5 and serum concentrations of the active metabolite are dependent on CYP2C19 function. 6 Additionally, CYP2C19 is an important metabolic enzyme of PPIs, but is also inhibited by some types of PPIs. 7 Therefore, the concomitant use of clopidogrel and a PPI could induce unwanted drug-drug interactions.
Accordingly, many pharmacodynamic studies have reported the attenuation of platelet function in vitro, suggesting that drug-drug interactions between clopidogrel and PPIs may occur in human patients. [8] [9] [10] [11] [12] [13] [14] [15] [16] These studies have raised debate about the clinical significance of this interaction. The only randomized clinical trial for the combined use of clopidogrel and a PPI, the COGENT trial (the Clopidogrel and the Optimization of Gastrointestinal Events Trial) showed that omeprazole did not increase the short-term (6 months) risk of major cardiovascular events in patients receiving aspirin and clopidogrel. 17 However, at least five cohort studies and a case-control study have reported increases in cardiovascular events and patient deaths when a PPI such as omeprazole was prescribed to patients treated with clopidogrel. [18] [19] [20] [21] [22] [23] Therefore, the selection of an appropriate gastric acid inhibitor for patients receiving clopidogrel remains an important clinical problem, 24 with the US Food and Drug Administration (FDA) discouraging the concomitant use of clopidogrel with omeprazole or esomeprazole (i.e., s-isomer of omeprazole). 25, 26 Vonoprazan belongs to a new class of gastric acid inhibitors that function as potassium-competitive acid blockers. Vonoprazaninduced acid inhibition is more potent than that of PPIs such as esomeprazole and rabeprazole. 27, 28 Furthermore, vonoprazan has been reported to be therapeutically superior to PPIs in treating reflux esophagitis and eradicating Helicobacter pylori. [29] [30] [31] In Japan, the standard dose of vonoprazan for patients receiving DAPT is 10 mg q.d. (single daily). 32 Vonoprazan is predominantly inactivated by CYP3A4, and partially by CYP2B6, CYP2C19, CYP2D6, and SULT2A1 (Figure S2) . 33 At the least, the H 1 ,K
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-ATPase inhibitory activity of major metabolites M-I, M-II, M-III, and M-IV-Sul are known to be 1/150 of vonoprazan (i.e., TAK-438). 32 The plasma concentrations and gastric acid inhibitory actions of vonoprazan therefore are less affected by polymorphisms of drug metabolizing enzymes, such as CYP2C19, than those of other PPIs. 27, 34 However, drug-drug interactions between vonoprazan and clopidogrel are yet to be elucidated.
Prasugrel, a third-generation thienopyridine agent, is also a prodrug that requires metabolism for activation ( Figure S3 ). Because prasugrel is predominantly metabolized to its active form, mainly by CYP3A and CYP2B6 with minor involvement of CYP2C9 and CYP2C19, 35 it may undergo drug-drug interactions with vonoprazan through CYP3A4. However, the effect of vonoprazan on the antiplatelet function of prasugrel has not been studied.
Importantly, there appears to be interethnic differences in the standard maintenance dose of prasugrel: in the USA and European countries the standard dose of prasugrel is 10 mg q.d., while in Japan it is 3.75 mg q.d. 36, 37 The equivalent dose to 10 mg in Western countries is 3.75 mg in Japan. 38, 39 Here we compared the effect of vonoprazan and esomeprazole on the antiplatelet function of clopidogrel and prasugrel at the standard doses in Japan with respect to CYP2C19 genotype in healthy Japanese volunteers.
RESULTS

Completion of the study protocol
As shown in Figure 1 , one homo-extensive (homo-EM) subject declined participation in the study before the 2 nd visit. Forty-two subjects started the study. However, the two poor metabolizers (PMs) were excluded because of drug-related nausea. Three subjects (two homo-EMs and one hetero-EM) dropped out: one homo-EM dropped out because of an accidental sports injury. Another homo-EM and the remaining hetero-EM declined to continue this study at their own request.
Thirty-seven subjects (17 homo-EMs, 12 hetero-EMs, and 8 PMs) completed the study according to the protocol from November 2015 to May 2016, giving a completion rate of 86% (37/43). There were no severe adverse events attributable to the drugs used in this study. However, in the quality control check by the clinical research coordinator (N.H.) after the entire study, six subjects (three homo-EMs and three hetero-EMs) were excluded from analysis because of poor drug compliance (<80%) in at least one of the six regimens assessed by e-mail and interview after each regimen. The remaining 31 subjects were analyzed as a per-protocol analysis set. However, the results of analysis without these six subjects (n 5 31) was approximately same as that with six subjects (n 5 37).
For the per-protocol set, there were no significant differences in the demographic or clinical characteristics among the three CYP2C19 genotypes ( Table 1) . Drug compliance was almost 100% for each regimen and CYP2C19 genotype (Table S1 ). There were no significant differences in compliance with each regimen among the three CYP2C19 genotypes.
Effect of esomeprazole and vonoprazan on the antiplatelet function of clopidogrel and prasugrel
We examined the effect of esomeprazole and vonoprazan on the antiplatelet function of clopidogrel and prasugrel in a crossover manner. Median inhibition of platelet aggregation (IPA) values (%) for clopidogrel (CLP) alone, clopidogrel 1 esomeprazole (EPZ), clopidogrel 1 vonoprazan (VPZ), prasugrel (PR) alone, prasugrel 1 esomeprazole, and prasugrel 1 vonoprazan for all subjects are shown in Figure 2 .
The median IPA value was highest for clopidogrel alone, followed by clopidogrel 1 esomeprazole, and then clopidogrel 1 vonoprazan (34%, 33%, and 14%, respectively, Figure 2 ). Vonoprazan significantly and more potently attenuated the antiplatelet function of clopidogrel than esomeprazole (33% with CLP 1 EPZ vs. 14% with CLP 1 VPZ (P < 0.001)).
The median IPA value was highest for prasugrel alone, followed by prasugrel 1 esomeprazole, and prasugrel 1 vonoprazan (59%, 47%, and 37%, respectively, Figure 2 ). Vonoprazan significantly and more potently attenuated the antiplatelet function of prasugrel than esomeprazole (47% with PR 1 EPZ vs. 37% with PR 1 VPZ (P 5 0.011)). Next we analyzed the influences of CYP2C19 genotype groups on the antiplatelet function of clopidogrel and prasugrel with or without esomeprazole or vonoprazan. The medians and ranges of the IPA value for the six different regimens as a function of CYP2C19 genotype are summarized in Figure 3 .
In clopidogrel-containing regimens (clopidogrel alone, clopidogrel 1 esomeprazole, and clopidogrel 1 vonoprazan), CYP2C19 genotype-dependent differences were observed in IPA values. Median IPA for clopidogrel alone was 48% for homoEMs, 38% for hetero-EMs, and 17% for PMs (P 5 0.001 between homo-EMs and PMs). Median IPA values for clopidogrel 1 esomeprazole in homo-EMs, hetero-EMs, and PMs were 40%, 36%, and 14% (P 5 0.002 between homo-EMs and PMs), while those for clopidogrel 1 vonoprazan were 21%, 20%, and 2%, respectively (P 5 0.029 between homo-EMs and PMs).
In contrast, median IPA values obtained with prasugrel were not influenced by CYP2C19 genotype irrespective of concomitant dosing with esomeprazole or vonoprazan ( Figure 3) .
Together, our results indicate that the effect of CYP2C19 function on platelet inhibition differed between clopidogrel and prasugrel. IPA values with clopidogrel were influenced by CYP2C19 genotype, whereas values with prasugrel were not, irrespective of concomitant dosing with esomeprazole or vonoprazan.
Effect of esomeprazole and vonoprazan on the antiplatelet function of clopidogrel and prasugrel with respect to CYP2C19 genotype
In homo-EMs, the median IPA with clopidogrel alone was 48%, which decreased when combined with esomeprazole (40%) and vonoprazan (21%), whereas the median IPA with prasugrel alone was 55%, which likewise decreased when combined with esomeprazole (48%) and vonoprazan (35%; Figure 4) . Therefore, only the clopidogrel 1 vonoprazan regimen resulted in an IPA of less than 30% in homo-EMs. In hetero-EMs, the median IPA value with clopidogrel alone was 38%, similar to that in combination with esomeprazole (36%), but decreased in combination with vonoprazan (20%). The median IPA with prasugrel alone was 59%, which decreased when combined with esomeprazole (43%) and vonoprazan (35%). Therefore, only the clopidogrel 1 vonoprazan regimen resulted in an IPA less than 30% in hetero-EMs.
In PMs, the median IPA with clopidogrel alone was 17%, which decreased when combined with esomeprazole (14%) and vonoprazan (2%); while the median IPA with prasugrel alone was 57%, which likewise decreased when combined with esomeprazole (50%) and vonoprazan (37%). Therefore, IPA values in PMs were less than 30% for all clopidogrel-containing regimens with or without esomeprazole and vonoprazan. However, median IPA values were all higher than 30% for prasugrel-containing regimens with or without vonoprazan and esomeprazole.
Therefore, the median IPA values obtained from the clopidogrel 1 vonoprazan regimen were less than 30% irrespective of CYP2C19 genotype. However, whether median IPA values for clopidogrel 1 esomeprazole were less than 30% depended on CYP2C19 genotype, while those for prasugrel were all higher than 30% irrespective of CYP2C19 genotype and concomitant use of esomeprazole or vonoprazan.
DISCUSSION
In this study we demonstrated that vonoprazan more potently attenuates the antiplatelet function of not only clopidogrel but also prasugrel in comparison with esomeprazole. The influence of vonoprazan on the antiplatelet function was greater for clopidogrel than for prasugrel. To our knowledge, this is the first study to show that vonoprazan attenuates the antiplatelet function of clopidogrel and prasugrel.
Because esomeprazole is a moderate inhibitor of CYP2C19 (time-dependent, 50% inhibition concentration (IC 50 ) 5 15 lM), 7, 40 esomeprazole effectively attenuated the antiplatelet function of clopidogrel. However, inhibition of CYP3A4 by esomeprazole is weak (concentration-dependent, inhibition constant (K i ) 5 46.6 6 6.8 lM), 41, 42 resulting in the level of the antiplatelet function of prasugrel with esomeprazole was not problematic in many cases: only 4 of 28 subjects (14%) who were initially categorized as "responders" with prasugrel alone became "low responders" when given prasugrel 1 esomeprazole ( Figure S4a) . Moreover, the antiplatelet function of prasugrel 1 esomeprazole was still superior to that of clopidogrel alone (Figure 2) .
On the other hand, active metabolization of prasugrel is mainly mediated by CYP3A4 35 ; therefore, vonoprazan, which is the moderate inhibitor of CYP3A4, as noted above, could attenuate the antiplatelet function of prasugrel.
In this study the effects of vonoprazan on the antiplatelet function of prasugrel and clopidogrel were more potent than that of esomeprazole. Vonoprazan acts as a moderate inhibitor of both CYP3A4 (time-dependent, IC 50 5 10 lM) and CYP2C19 (time-dependent, IC 50 5 13 lM). 32 Dual inhibition of CYP2C19 and CYP3A4 by vonoprazan could result in strong attenuation of the antiplatelet function of clopidogrel. Interestingly, the plasma half-life of vonoprazan is 7.7 h, 32 which is much longer than the 1.08 h of esomeprazole. 43 This might also explain why vonoprazan more strongly attenuates the antiplatelet function of clopidogrel and prasugrel than esomeprazole.
The level of antiplatelet attenuation following administration of clopidogrel together with esomeprazole was dependent on CYP2C19 genotype. Especially in hetero-EMs and PMs of CYP2C19, the efficacy of clopidogrel was unstable with concomitant use of esomeprazole: four of nine hetero-EMs (44%) and six of eight PMs (75%) reached a "low responder" level when given esomeprazole 1 clopidogrel ( Figure S5a) . These results suggest that hetero-EMs and PMs could be at a higher risk of becoming a "low responder" to clopidogrel, especially when combined with esomeprazole.
With vonoprazan, the antiplatelet function of clopidogrel was potently attenuated even in homo-EMs, with 9 of 14 homo-EMs (64%) categorized as "low responders" (Figure S5b ). Based on these data, we suggest avoiding the concomitant use of clopidogrel and vonoprazan in all CYP2C19 genotype groups.
Our results should be interpreted within the context of several limitations. First, the number of subjects whose data were analyzed was not so large (n 5 31). However, we could clearly detect the significant difference of antiplatelet effect attenuation between esomeprazole and vonoprazan because the difference was large. Independent repetition of this study is desirable to draw firm conclusions. Second, we planned to use only one whole-blood platelet function test (i.e., VerifyNow, UMIN 000019901). Although the VerifyNow assay is a useful predictor of long-term clinical outcomes in patients with acute coronary syndrome, 44 future examination using plural methods is desirable. Third, the maintenance doses of prasugrel, used in the current study (3.75 mg/day), corresponded to the standard dose used in Japan, 35 which is lower than those in the USA and Europe. Because there is an ethnic difference in the reactivity to prasugrel, the equivalent dose to 10 mg in Western countries is 3.75 mg in Japan. 38, 39 Therefore, to be more precise, our results should be confirmed in USA and European patients. Fourth, we did not measure the *17 allele of CYP2C19, because the incidence of *17 in our population is very low (i.e., 1.7%). 45 Therefore, the effect of CYP2C19*17 is difficult to analyze in our ethnic group and we could not plan to involve CYP2C19*17 in the analysis (UMIN 000019901). Finally, we did not measure the plasma concentration of active metabolites of clopidogrel and prasugrel, and so we were unable to evaluate the relationship between the plasma levels of these two agents and P2Y12 assay profiles.
With these limitations in mind, our results have clearly demonstrated that vonoprazan is a potent inhibitor of the antiplatelet functions of clopidogrel and prasugrel. In other words, vonoprazan should be recognized as not only the inhibitor of CYP3A4 but also the inhibitor of CYP2C19. Although vonoprazan is therapeutically superior to PPIs for treating gastroesophageal reflux disease and eradicating H. pylori, these data should be considered when vonoprazan is prescribed to patients receiving clopidogrel or prasugrel. Prasugrel is less affected by the CYP2C19 genotype and concomitant use of esomeprazole. Further clinical studies are needed to determine the risk:benefit ratio of coadministering vonoprazan or esomeprazole to patients already treated with clopidogrel or prasugrel.
METHODS
Quality management to observe Good Clinical Practice guidelines
The study protocol was approved by the Human Institutional Review Board of the Hamamatsu University School of Medicine, Hamamatsu, Japan (RG15-054), and the study was registered with the Japanese clinical trial registry system (UMIN 000019901). To ensure study quality, the study was managed by medical doctors who had completed Good Clinical Practice Education and Training (CITI Japan, e-learning program) and monitored by a clinical research coordinator (N.H.) from the Hamamatsu University School of Medicine.
Primary endpoint
We aimed to compare the effect of vonoprazan and esomeprazole on the antiplatelet functions of clopidogrel and prasugrel. We also assessed the effect of CYP2C19 genotype on the antiplatelet functions of clopidogrel and prasugrel in the presence or absence of esomeprazole and vonoprazan.
Subjects, case report form, and ALCOA Volunteers were recruited among medical and nursing students of Hamamatsu University School of Medicine from November 24 to December 22, 2015 (Figure 1) . Criteria for volunteer recruitment are shown in Table S2 . All volunteers (n 5 50) were young, healthy Japanese males and females, of whom 47 provided written informed consent. They were administered questionnaires and subjected to health checks and blood sampling, including measurement of serum anti-H. pylori IgG and CYP2C19 polymorphism. Key exclusion criteria are shown in Table S2 . Three volunteers for whom we had difficulty collecting blood samples and one volunteer seropositive for H. pylori infection were excluded. The remaining 43 were enrolled and case report forms (CRFs) were prepared. CRFs were filled out in accordance with the FDA's ALCOA (Attributable, Legible, Contemporaneous, Original, and Accurate) guidelines. 25 Serum H. pylori IgG analysis Serum anti-H. pylori IgG was analyzed by a commercial company (BML, Tokyo, Japan: ISO 15189, certification number: RML00010) using a commercial kit (E-plate Eiken H. pylori antibody; Eiken Chemical, Tokyo, Japan). Volunteers with titers of <10 U/mL were diagnosed as H. pylori-negative.
CYP2C19 genotyping DNA was isolated from white blood cells with a commercially available kit (Wizard Genomic DNA Purification Kit; Promega, Madison, WI). Polymorphic analyses of CYP2C19 were performed with an automated gene analyzer (Genecube; Toyobo, Osaka, Japan).
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CYP2C19 genotypes are now classified into four groups: ultrarapid metabolizer (URM), homo-EM, hetero-EM, and PM. However, the population frequency of URM in Japan is very low (1.7%), 45 and CYP2C19 genotyping for patients taking PPIs or thienopyridines are now commonly limited to three types. Namely, in this study, the subjects were classified into homo-EM (CYP2C19 *1/*1, including URM), hetero-EM (*1/*2 or *1/*3), and PM (*2/*2, *2/*3 or *3/*3).
P2Y12 assay P2Y12 assay was performed using the "VerifyNow System" and "VerifyNow P2Y12 assay kit" (Accumetrics, San Diego, CA) in accordance with the manufacturer's protocol. When we started the VerifyNow system, we calibrated the system using the EQC (electronic quality control) to minimize interassay variance.
Study protocol and randomization
The study was designed by the chief strategist of our study group (Prof. T. Furuta). Subjects first underwent a baseline P2Y12 assay without medication to exclude those with abnormal platelet function ( Figure 1 ). We then tested six different single daily regimens in a crossover manner as follows: 1) clopidogrel (Plavix; Sanofi, Tokyo, Japan) 75 mg alone; 2) clopidogrel 1 esomeprazole (Nexium; AstraZeneca, Osaka, Japan) 20 mg; 3) clopidogrel 1 vonoprazan (Takecab; Takeda Pharmaceutical, Osaka, Japan) 10 mg; 4) prasugrel (Effient; Daiichi-Sankyo, Tokyo, Japan) 3.75 mg alone; 5) prasugrel 1 esomeprazole; and 6) prasugrel 1 vonoprazan. The order of the six regimens was randomized using a random number table, and the order assigned to individual subjects was recorded on their CRF at the time of enrollment (Figure 1) . The washout period between each regimen was at least 2 weeks. Doses of clopidogrel (75 mg) and prasugrel (3.75 mg) in this study are standard doses in Japan.
Experimental procedure for P2Y12 assay For the control study ( Figure S6 (2  nd visit) ), blood sample collection was performed at 8:30 a.m. without medication for baseline IPA.
For the crossover study ( Figure S6 (3 rd -8 th visit)), all doses were administered at 8:30 a.m. Food intake was prohibited from waking until 9:30 a.m., although water was permitted ad libitum. Each subject received a reminder email, which included their regimen, at 8:30 a.m. every morning, and drug compliance was confirmed by a reply email from each subject confirming completion of their daily drug protocol. Blood sample collection was performed at 8:30 a.m. (i.e., trough level timing) on Day 7 of each regimen via the median cubital, basilic, or cephalic veins. Particular care was taken to ensure a smooth puncture with minimum blood congestion. We discarded the first 5 ml of blood and then collected two blood samples into 1.8-ml siliconized glass tubes containing 3.2% trisodium citrate (VenoJect II, Terumo, Tokyo, Japan).
The P2Y12 assay processes of these two samples were performed between 9:00 a.m. to 0:30 p.m. following the procedure outlined in the operation manual. 47 IPA values were measured for each sample and transcribed onto the subject's CRF. Using the values from the two samples, we calculated the median IPA as a measure of the antiplatelet function for each regimen ( Figure S6 ). The variability between the two samples in every case was not large and within acceptable limits.
Calculation of IPA and definition of "low responder" The VerifyNow system reported the PRU (P2Y12 reaction unit), and automatically calculated the IPA using the following formula: IPA 5 ((PRU predrug -PRU postdrug)/PRU predrug) 3 100%. 47 There were no missing data when statistical analysis was performed. A subject with an IPA <30% was defined as a "low responder." [48] [49] [50] Sample size and statistical analysis This is the first study to investigate the effect of vonoprazan on the antiplatelet functions of clopidogrel and prasugrel. Consultation with a biostatistician recommended an ideal sample size of 30 (15 homo-EMs, 15 (hetero-EMs 1 PMs)). Since the Japanese population frequency of CYP2C19 genotypes is 35.5% for homo-EMs, 43.8% for hetero-EMs, and 18.8% for PMs, 45 we expected that 42 eligible volunteers would be necessary to enroll 15 homo-EMs (15/0.355). Furthermore, we expected a 20% exclusion rate in the eligibility assessment of volunteers. Accordingly, 50 volunteers (42*1.2) were recruited (Figure 1) , among whom 43 were eligible and enrolled as subjects.
To determine the demographics of our subjects, statistical analysis of male:female ratios for the three CYP2C19 genotypes was performed using Fisher's exact test. Age, height, and weight are presented as means 6 standard deviations (SD). Significant differences in age, height, and weight among the three genotypic groups were analyzed using oneway analysis of variance (ANOVA).
Subjects who completed all examinations up to the 8 th visit with good drug compliance (80% in each regimen) were entered into the perprotocol analysis set ( Figure 1) . For this set, we calculated the median for drug compliance and IPA. Statistically significant differences in median IPA values among the regimens, including baseline, were determined using the Freidman test followed by the Wilcoxon signed-rank test. Differences in IPA values among the three CYP2C19 genotypes in each regimen were determined using the Kruskal-Wallis test followed by the Mann-Whitney U-test.
All statistical calculations were performed using IBM SPSS Statistics v. 23 (IBM, NC). All P values were two-tailed, and P < 0.050 indicated statistical significance. 
